Cell Therapy Development
Leveraging the power of induced pluripotent stem cells (iPSCs) for cell therapies with the potential to fulfill unmet medical needs.
Innovation designed to cure diseases
Fujifilm is changing drug discovery and healthcare, using new technologies in biologically derived materials to develop new scientific tools, fuel the race to cure cellular-based diseases, and advance the field of cell-based therapy where healthy cells are integrated into the body to replace diseased tissue. In 2014, Fujifilm acquired a majority stake in Japan Tissue Engineering to focus on tissue engineering/regeneration, and in 2015, acquired Cellular Dynamics International, a leading American producer of induced pluripotent stem cells (iPSC) and differentiated tissue-specific cell types.
Fujifilm continues to make critical investments in enhancing cell therapy R&D efforts through expansion into cell and tissue GMP manufacturing facilities and new projects, such as Opsis Therapeutics, a joint venture focused on developing regenerative medicine therapies in the fields of macular degeneration and inherited retinal diseases.
Any therapeutic options referred to on this page are generally subject to local regulatory approval and may still be at development stage or may only be authorized in certain territories such as Japan. In particular, no such regulatory approvals exist in the EU and US. A use and commercialization in the future or in other regions will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.